Health Care International - GPC Biotech Opens Enrollment In Phase 1 Trial Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor In Patients With Advanced Solid Tumors
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid tumors. This is the first time that this novel drug candidate is being s
Comments